|
Gene: PTRF |
Gene summary for PTRF |
Gene summary. |
Gene information | Species | Human | Gene symbol | PTRF | Gene ID | 284119 |
Gene name | caveolae associated protein 1 | |
Gene Alias | CAVIN | |
Cytomap | 17q21.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6NZI2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
284119 | PTRF | AEH-subject1 | Human | Endometrium | AEH | 7.64e-34 | -5.31e-01 | -0.3059 |
284119 | PTRF | AEH-subject2 | Human | Endometrium | AEH | 3.44e-31 | -5.31e-01 | -0.2525 |
284119 | PTRF | AEH-subject3 | Human | Endometrium | AEH | 1.95e-33 | -5.31e-01 | -0.2576 |
284119 | PTRF | AEH-subject4 | Human | Endometrium | AEH | 3.34e-24 | -5.31e-01 | -0.2657 |
284119 | PTRF | AEH-subject5 | Human | Endometrium | AEH | 1.95e-33 | -5.31e-01 | -0.2953 |
284119 | PTRF | EEC-subject1 | Human | Endometrium | EEC | 8.01e-32 | -5.31e-01 | -0.2682 |
284119 | PTRF | EEC-subject2 | Human | Endometrium | EEC | 2.98e-34 | -5.31e-01 | -0.2607 |
284119 | PTRF | EEC-subject3 | Human | Endometrium | EEC | 6.74e-36 | -5.31e-01 | -0.2525 |
284119 | PTRF | EEC-subject4 | Human | Endometrium | EEC | 2.98e-34 | -5.31e-01 | -0.2571 |
284119 | PTRF | EEC-subject5 | Human | Endometrium | EEC | 1.16e-34 | -5.31e-01 | -0.249 |
284119 | PTRF | GSM5276934 | Human | Endometrium | EEC | 2.59e-36 | -5.31e-01 | -0.0913 |
284119 | PTRF | GSM5276935 | Human | Endometrium | EEC | 1.16e-34 | -5.31e-01 | -0.123 |
284119 | PTRF | GSM5276937 | Human | Endometrium | EEC | 2.35e-29 | -5.31e-01 | -0.0897 |
284119 | PTRF | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.43e-25 | -5.31e-01 | -0.1869 |
284119 | PTRF | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 8.55e-23 | -5.31e-01 | -0.1875 |
284119 | PTRF | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.84e-26 | -5.31e-01 | -0.1883 |
284119 | PTRF | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.16e-34 | -5.31e-01 | -0.1934 |
284119 | PTRF | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 6.74e-36 | -5.31e-01 | -0.1917 |
284119 | PTRF | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 4.20e-34 | -5.31e-01 | -0.1916 |
284119 | PTRF | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 4.51e-35 | -5.31e-01 | -0.1269 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTRF | SNV | Missense_Mutation | novel | c.577N>A | p.Glu193Lys | p.E193K | Q6NZI2 | protein_coding | tolerated(0.16) | benign(0.232) | TCGA-EY-A1GS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | PD |
PTRF | SNV | Missense_Mutation | c.881N>A | p.Arg294Gln | p.R294Q | Q6NZI2 | protein_coding | tolerated(0.13) | benign(0.027) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PTRF | SNV | Missense_Mutation | novel | c.776N>T | p.Thr259Ile | p.T259I | Q6NZI2 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PTRF | SNV | Missense_Mutation | rs144331065 | c.893N>A | p.Arg298His | p.R298H | Q6NZI2 | protein_coding | deleterious(0.01) | possibly_damaging(0.823) | TCGA-2Y-A9GS-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
PTRF | SNV | Missense_Mutation | rs758025496 | c.355G>A | p.Val119Ile | p.V119I | Q6NZI2 | protein_coding | tolerated(0.1) | benign(0.115) | TCGA-2Y-A9GV-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Targeted Molecular therapy | sorafenib | PD |
PTRF | SNV | Missense_Mutation | c.260A>T | p.Gln87Leu | p.Q87L | Q6NZI2 | protein_coding | tolerated(0.14) | benign(0.01) | TCGA-DD-A1EF-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
PTRF | SNV | Missense_Mutation | c.973N>A | p.Val325Ile | p.V325I | Q6NZI2 | protein_coding | tolerated(0.19) | probably_damaging(0.995) | TCGA-DD-A73C-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
PTRF | SNV | Missense_Mutation | c.988N>A | p.Glu330Lys | p.E330K | Q6NZI2 | protein_coding | deleterious(0.05) | possibly_damaging(0.704) | TCGA-44-3396-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | alimta | SD | |
PTRF | SNV | Missense_Mutation | novel | c.680G>T | p.Arg227Leu | p.R227L | Q6NZI2 | protein_coding | deleterious(0.01) | possibly_damaging(0.614) | TCGA-73-7498-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | pemetrexed | CR |
PTRF | SNV | Missense_Mutation | novel | c.1085N>C | p.Arg362Pro | p.R362P | Q6NZI2 | protein_coding | tolerated(0.18) | benign(0.191) | TCGA-58-A46M-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |